

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.ejcancer.com](http://www.ejcancer.com)

## Corrigendum

## Corrigendum to ‘A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours’ [Eur J Cancer 104 (November 2018) 1–8]



Anas Gazzah <sup>a,\*</sup>, Valentina Boni <sup>b</sup>, Jean-Charles Soria <sup>a</sup>, Antonio Calles <sup>b,c</sup>, Caroline Even <sup>d</sup>, Bernard Doger <sup>e</sup>, Linda Mahjoubi <sup>a</sup>, Rastislav Bahleda <sup>a</sup>, Mahmoud Ould-Kaci <sup>f</sup>, Anne Esler <sup>g</sup>, Serge Nazabadioko <sup>h</sup>, Emiliano Calvo <sup>b</sup>

<sup>a</sup> Drug Development Department, Gustave Roussy Cancer Campus, 114 Rue Édouard-Vaillant, 94805 Villejuif Cedex, France

<sup>b</sup> Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain

<sup>c</sup> Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Calle Del Dr. Esquerdo, 46, 28007 Madrid, Spain

<sup>d</sup> Department of Head and Neck Cancer, Gustave Roussy Cancer Campus, 114 Rue Édouard-Vaillant, 94805 Villejuif Cedex, France

<sup>e</sup> Medical Oncology Phase I Unit, START Madrid Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain

<sup>f</sup> Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA

<sup>g</sup> Statistics, Syneos Health, 3201 Beechleaf Court, Raleigh, NC 27604, USA

<sup>h</sup> Medical Department, Boehringer Ingelheim, 12 Rue André Huet, 51721 Reims, France

The authors regret that after publication, the author Emiliano Calvo would like to express the interest of disclosing all his interactions with industry, although not directly relevant to the published work, in the spirit of full transparency. His updated Declaration of Interests disclosure is below. The authors would like to apologize for any inconvenience.

### Emiliano Calvo updated declaration of interests

Emiliano Calvo is employed by START and HM Hospitals Group, where he holds a leadership position;

DOI of original article: <https://doi.org/10.1016/j.ejca.2018.07.011>.

\* Corresponding author: Gustave Roussy Cancer Campus and University Paris-Sud, 114 Rue Édouard-Vaillant, 94805 Villejuif Cedex, France.

E-mail address: [anas.gazzah@gustaveroussy.fr](mailto:anas.gazzah@gustaveroussy.fr) (A. Gazzah).

he has ownership at START, Oncoart Associated and International Cancer Consultants; he receives honoraria from HM Hospitals Group, and he is the founder and president of NPO foundation INTHEOS (Investigational Therapeutics in Oncological Sciences). In the last two years, he has been a paid consultant or advisor to Novartis, Nanobiotix, Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, EUSA Pharma, Abbvie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, GLG, Pfizer, Servier and Amcure; he is part of a Speakers' Bureau to Novartis; he has received research funding from AstraZeneca, Novartis, BeiGene and START and he has received travel financial support from Roche/Genentech.

<https://doi.org/10.1016/j.ejca.2018.12.018>

0959-8049/© 2018 Published by Elsevier Ltd.